A Belgian startup building a brain implant that restores sight by feeding visual signals directly into the visual cortex (bypassing the eye and optic nerve entirely) closed an oversubscribed €4 million seed round in May 2026, two months after winning FDA Breakthrough Device Designation and four months before its first-in-human trial is scheduled to begin. ReVision Implant is now bringing manufacturing of its Occular cortical vision prosthesis in-house ahead of the first-in-human surgical-window cohort planned for October 2026. The company expects to start the early-stage clinical trial in blind volunteers in summer 2027 if regulatory approvals hold.

What ReVision is building

The Occular device is a cortical visual prosthesis intended to restore functional vision in people with severe blindness. Rather than attempting to repair damaged eyes, retinas, or optic nerves, the device interfaces directly with the brain’s visual cortex, bypassing the entire upstream visual pathway. An external camera captures visual information, processes it, and transmits the patterns of stimulation to the cortical electrode array, which in turn evokes patterns of artificial sight in the patient’s perception. The architecture targets patients whose blindness sits anatomically downstream of the retina, where retinal prostheses cannot help.

The round and the use of proceeds

ReVision Implant raised €4 million in an oversubscribed seed round from private investors. The company has not publicly named a lead investor. The capital will fund continued development through the first-in-human trial scheduled for Q3 2026 and the early-stage clinical trial in blind volunteers expected in summer 2027.

A material portion of the proceeds is earmarked for in-house manufacturing infrastructure. ReVision began standing up its own cleanroom facilities approximately three months ago, with the intent of bringing critical manufacturing steps in-house ahead of clinical trials. For a Class III implantable device, control over production is a regulatory and commercial moat. The strategic logic is similar to the silicon-supplier-plus-clinical-sponsor model Inside BCI tracked on 19 May with MintNeuro and Motif Neurotech, but applied with vertical integration on the implant manufacturing side rather than horizontal supply chain partnerships.

How this fits the vision restoration cohort

ReVision Implant is the third Western vision restoration company Inside BCI has covered in active 2026 clinical or regulatory progression, alongside the Illinois Institute of Technology / Rush ICVP consortium (third implant 7 May 2026, 34 wireless stimulators, 544 electrodes) and Science Corporation’s PRIMA sub-retinal photovoltaic chip (CE Mark submitted June 2025, EU approval targeted mid-2026). Neuralink’s Blindsight is the fourth platform in the cohort, with first-in-human targeted for 2026 per Elon Musk’s public statements but no implantation disclosed to date.

The four platforms target different anatomical sites. ReVision Implant’s Occular stimulates the visual cortex, putting it architecturally adjacent to ICVP and Blindsight. Science Corporation’s PRIMA stimulates the retina, which serves a narrower addressable indication (geographic atrophy in age-related macular degeneration where the retina is partially intact). The €4 million round positions ReVision at a much smaller capital base than Neuralink or Science Corporation but extends the European-public-research neurotechnology pattern that anchors much of our recent coverage.

Why the cleanroom matters

The decision to manufacture the Occular device in-house is unusual for a seed-stage neurotechnology company. Most BCI and vision-restoration companies at this stage outsource implant manufacturing to specialised contract manufacturers (Microprobes for Life Science and Sigenics are the recurring names in the cohort). ReVision’s cleanroom investment signals one of two strategic positions: either the company believes its electrode architecture requires manufacturing know-how that does not exist in external contract manufacturers, or it is positioning for FDA Class III approval where production control is a substantive regulatory advantage.

Both positions hold even without the other. The cleanroom investment is therefore a meaningful capital-allocation decision, not just an operational detail. It commits the company to a vertical integration trajectory that other vision-restoration peers have not chosen.

What to watch

The first signal is the October 2026 surgical-window cohort: ReVision plans to implant the Occular device during scheduled brain surgeries (where the patient is already opened for an unrelated procedure) to gather acute intraoperative data ahead of the chronic study. The second signal is the summer 2027 early-stage clinical trial in blind volunteers, which is the formal first-in-human chronic implantation event. The third signal is whether ReVision raises a Series A within the next 12-18 months to fund the longer clinical pathway through pivotal trials, and at what valuation the next round prices relative to the European vision-restoration peer set.

Sources

• Revision Implant lands oversubscribed €4m round to take brain-powered sight implant into the clinic (Business Matters Magazine)
• The bionic eye: ReVision Implant lands €4M for a vision device that feeds directly into your brain (Tech Funding News)
• ReVision Implant secures €4M to advance vision restoration technology (Tech.eu, 26 May 2026)
• FDA grants breakthrough device designation to ReVision Implant visual cortex prosthesis (Med-Tech Insights, March 2026)
• ReVision Implant Seed Round (Crunchbase)
• ReVision Implant eyes FIH trial for BCI after FDA breakthrough designation (Medical Device Network)